All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
May 12, 2020 saw the early release of results from the phase III IKEMA (NCT03275285) trial following recommendation from an Independent Data Monitoring Committee.1 The randomized, open label, multicenter study evaluated the clinical benefit of the anti-CD38 agent, isatuximab, in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone alone in patients with relapsed and/or refractory (RR) multiple myeloma (MM; RRMM) following 1 ‒ 3 prior lines of therapy.2
In this first planned interim analysis of the IKEMA trial, the addition of isatuximab to the carfilzomib plus dexamethasone regimen was associated with significantly improved progression-free survival (PFS) rates in patients with RRMM when compared to carfilzomib and dexamethasone alone. These data fulfil the primary endpoint for this study and no new safety concerns were observed.
Isatuximab recently received approval in Europe and the US for the treatment of RRMM in combination with pomalidomide and dexamethasone.
Sanofi. Sarclisa® (isatuximab) Phase 3 IKEMA trial meets primary endpoint early in patients with relapsed multiple myeloma Paris Stock Exchange:SAN. globenewswire. https://www.globenewswire.com/news-release/2020/05/12/2031604/0/en/Sarclisa-isatuximab-Phase-3-IKEMA-trial-meets-primary-endpoint-early-in-patients-with-relapsed-multiple-myeloma.html. Published May 12, 2020. Accessed May 12, 2020.
Clinicaltrials.gov. Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients . https://clinicaltrials.gov/ct2/show/NCT03275285. Updated March 10, 2020. Accessed May 12, 2020.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox